作者：
James,Tumlin [1]
;
Brad,Rovin [2]
;
Hans-Joachim,Anders [3]
;
Eduardo F,Mysler [4]
;
David R W,Jayne [5]
;
Tsutomu,Takeuchi [6]
;
Catharina,Lindholm [7]
;
Gudrun,Weiss [8]
;
Alessandro,Sorrentino [8]
;
Kevin,Woollard [9]
;
Nicola,Ferrari [10]
作者单位：
NephroNet Clinical Trials Consortium, Buford, Georgia, USA.
[1]
Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
[2]
Division of Nephrology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
[3]
Organizacion Medica de Investigación, Buenos Aires, Argentina.
[4]
Department of Medicine, University of Cambridge, Cambridge, UK.
[5]
Department of Rheumatology and Applied Immunology, Saitama Medical University and Division of Rheumatology, Department of Internal Medicine, Keio University, Tokyo, Japan.
[6]
BioPharmaceuticals R&D, AstraZeneca R&D, Gothenburg, Sweden.
[7]
Global Medical Affairs, Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
[8]
Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
[9]
Translational Science and Experimental Medicine, Early R&I, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
[10]
DOI
10.1016/j.ekir.2024.10.013
PMID
39810777
发布时间
2025-01-15
换一批
换一批
